By Dr. Quoc N. Dang, DO | May 2026
There is a window between normal metabolic function and type 2 diabetes that medicine has historically been bad at treating. Prediabetes affects an estimated 98 million American adults. Most of them don’t know they have it. A fraction receive any meaningful intervention. And a significant proportion, roughly 5 to 10 percent per year, go on to develop type 2 diabetes on a timeline that is not inevitable but has been treated that way for too long.
The conversation is changing. GLP-1 receptor agonists, developed initially for glycemic management in established type 2 diabetes, have accumulated enough evidence in the prediabetes and high-risk obesity population to reframe how we think about diabetes prevention as a prescribable intervention rather than a lifestyle counseling footnote. The patients sitting in primary care offices with elevated fasting glucose and a BMI over 30 deserve to know what is now available to them.
The Prediabetes Problem
Prediabetes is defined by a fasting glucose between 100 and 125 mg/dL, a two-hour glucose between 140 and 199 mg/dL on an oral glucose tolerance test, or an HbA1c between 5.7 and 6.4 percent. It represents a state of impaired insulin sensitivity and progressively failing compensatory insulin secretion that, left unaddressed, tends to worsen over time rather than spontaneously resolve.
The landmark Diabetes Prevention Program trial established that intensive lifestyle intervention producing 5 to 7 percent weight loss could reduce progression from prediabetes to type 2 diabetes by 58 percent over three years. Metformin reduced it by 31 percent. Those results were meaningful. They were also achieved in a highly controlled trial environment with resources, follow-up intensity, and participant motivation that do not translate reliably to real-world clinical practice. The 5 to 7 percent weight loss target that drives the lifestyle benefit is exactly the range at which behavioral interventions alone have the poorest long-term maintenance.
Modern weight loss medication is now positioned to fill that gap. A medication that reliably produces 12 to 20 percent weight loss while specifically targeting visceral fat, improving insulin sensitivity, and reducing fasting glucose addresses the pathophysiology of prediabetes at a scale that lifestyle intervention alone rarely achieves.
What the GLP-1 Trial Data Shows for Diabetes Risk
The STEP 1 trial for semaglutide enrolled adults with obesity or overweight and at least one comorbidity, excluding those with established type 2 diabetes. Among participants who met prediabetes criteria at baseline, a substantial majority reverted to normoglycemia by 68 weeks. The proportion of participants with prediabetes at baseline who no longer met criteria by trial end was significantly higher in the semaglutide group than placebo. That is categorical reversal of a disease state, not just incremental improvement in a lab value.
The SURMOUNT-1 trial for tirzepatide produced comparable findings in a larger population. A post-hoc analysis found that over 90 percent of participants with prediabetes at baseline had reverted to normal glucose by 72 weeks in the tirzepatide groups, compared to approximately half in the placebo group. The SELECT cardiovascular outcomes trial added another dimension: semaglutide reduced the incidence of new-onset type 2 diabetes by 73 percent over a median of 39 months in a high-risk population with obesity and established cardiovascular disease but no diabetes at baseline. That is a sustained, large-magnitude effect on incident disease that goes well beyond what glycemic trial endpoints typically capture.
Why Weight Loss Drives the Effect
The primary mechanism behind the diabetes prevention signal is visceral fat reduction. Visceral adipose tissue drives hepatic insulin resistance, impairs glucose disposal in skeletal muscle, and creates the progressive beta cell stress that characterizes prediabetes progression. When visceral fat is substantially reduced, as it consistently is with GLP-1 receptor agonist treatment, the insulin resistance underlying prediabetes is attenuated at its source rather than managed downstream.
There are also weight-independent effects. GLP-1 receptor agonists directly improve pancreatic beta cell function, enhance glucose-dependent insulin secretion, and suppress inappropriate glucagon release. These effects operate on the same pathophysiology defining prediabetes independently of what is happening with body weight. Patients who show modest weight loss on these medications often show disproportionate glycemic benefit. The two mechanisms reinforce each other rather than overlap.
Who Should Be Having This Conversation
The patient profile that most clearly warrants a discussion about GLP-1 weight loss medication for diabetes prevention is straightforward: BMI above 30, fasting glucose in the prediabetes range or HbA1c between 5.7 and 6.4, and a history of insufficient response to lifestyle intervention. That description fits a large proportion of patients seen in primary care every day. Many of them have been told to watch their diet and come back in six months, repeatedly, for years.
The SELECT and STEP data now provide a clinical argument for doing something more substantive. A medication that reduces incident type 2 diabetes by 73 percent in a high-risk population while simultaneously reducing major cardiovascular events by 20 percent, improving blood pressure and lipids, and producing meaningful weight loss is not a peripheral option for this patient. For anyone at this stage weighing their choices, a detailed comparison of currently approved
For anyone at this stage researching their options, a comparison of currently approved weight loss medication options, including how each performs on glycemic outcomes and what the realistic timelines look like, is a useful starting point before the clinical conversation.
The Timing Argument
Prediabetes is a reversible state. Type 2 diabetes, once established, requires lifelong management of a condition that has already produced beta cell damage that cannot be fully recovered. The window for meaningful prevention is not infinite.
Patients treated with effective weight loss medication while still in the prediabetes stage, before significant beta cell reserve has been lost, have the best chance of sustained remission rather than delayed progression. That argument applies with less force once established diabetes has been present for several years. The case for early intervention is not just that it prevents diabetes. It is that it prevents the version of diabetes that is hardest to reverse.
The evidence now supports making that case explicitly, with specific medications and specific expected outcomes, rather than defaulting to a lifestyle counseling plan that the data shows will not be sufficient for most patients in this risk category. That is the conversation the prediabetes population deserves to be having, and it is one that primary care clinicians are increasingly well-positioned to lead.
___
Dr. Quoc N. Dang, DO, is a board-certified physician and Medical Director at WeightLossPills.com.
